"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

Esketamine, the S isomer of ketamine, has already gained approval for treatment-resistant depression under the trademark Spravato; psilocybin and ketamine have been shown to provide benefits to ...

XWPharma developed XW10508 as an esketamine-based therapy with an optimized therapeutic index. XW10508 is a glutamatergic NMDA antagonist and AMPA activator designed for the treatment-resistant ...

These results show a strong correlation between patient- and physician-reported measures and the promise of esketamine ...

during the treatment period, though more participants experienced headache in the CT-152 group (2.1% vs 1.6%). Impact of ...

Mental health is a vital aspect of overall well-being, especially for students who face unique pressures and challenges. From ...

it is important that ketamine treatment be administered in a medically supervised setting. Esketamine is currently FDA-indicated as an adjunctive treatment after two failed antidepressant trials.

Roy Perlis is the director of the Center for Quantitative Health at Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School. Stephen Morrissey, the interviewer, is ...

In contrast, esketamine targets glutamate ... "I have no doubt in my mind that this is a very useful treatment," Gerard Sanacora, a psychiatrist and the director of the Yale Depression Research ...

Currently accepting new clients for Spravato (Esketamine) treatment! I have been a Board Certified Psychiatric Nurse Practitioner for five years, working in Bangor Maine for the bulk of that time.

Relevance is one of the only facilities that offer Spravato (esketamine) treatment for major depressive disorder, which can be covered by most insurance carriers. Choose Relevance Behavioral ...